KIYATEC & Cancer

KIYATEC has identified patient-specific diagnostics as a tangible development goal for future clinical application of the company's novel 3DKUBE™ technology platform.  Early experimental efforts have demonstrated the system's ability to maintain viable tumor tissue in vitro for use in downstream diagnostic protocols.  Personalized medicine (optimal drug identified for each patient) represents the future of cancer care and KIYATEC is working to deliver on that dream.

The Future of Cancer Care

The future of cancer care requires advanced diagnostics to assist physicians in actively selecting the most effective therapeutic for each and every patient.  Accurate in vitro modeling of an individual's disease-state requires a degree of complexity that involves multiple cell types and interactions that is currently unmet by traditional "Petri Dish" two-dimensional (2D) cell culture.  As a demonstration of this fact, a 2010 study conducted by researchers at Stanford University showed that traditional 2D cell culture models had a 0.0 correlation with the human condition while 3D cell culture models represented a higher human correlation than even mouse models¹.  This evidence supports the opportunity to use advanced 3D cell culture techniques in evaluating patient drug response in a personalized fashion.

¹  T Ridky, et al. Nature Medicine 2010.

Clinical Partnership for Success

KIYATEC has joined a select group of private industry partners in collaboration with the Institute for Translational Oncology Research (ITOR) of Greenville Hospital System University Medical Center.  As a phase one clinical site dedicated to cutting-edge cancer care, ITOR's Clinical Research Unit manages an average of 20 active clinical trials, including a number of first-in-man studies.  As a result of the partnership, KIYATEC has taken the next step to physically relocate the company's R&D operations within the ITOR research laboratory space.  Connectivity with pharmaceutical partners and the oncology clinical center provides valuable feedback and insights necessary to effectively translate the company's core technology into clinically-relevant diagnostics useful for the future of patient-specific cancer care.